Designed using traditional approach, Novavax vaccine gets review by FDA advisory panel on Tuesday.
With three COVID vaccines already authorized by the U.S. Food and Drug Administration, Americans have easy access to plenty of shots.
“I’m likely going to recommend this for my parents, who are age 84 and 87, for their fifth dose this fall,” said UC San Francisco infectious disease specialist Dr. Monica Gandhi. On Tuesday, the vaccine must pass a critical milestone when a panel of outside experts will recommend — or reject — that the FDA authorize the vaccine. Data show that Novavax is 96% effective in preventing severe disease or death and 90% protective against infection, comparable to Moderna and Pfizer. This data was collected before the more contagious omicron and its subvariants started widely circulating.
But there are concerns about a small number of cases of rare heart inflammation, which caused the biotech company’s share price to plummet 18% on Monday. Similar problems led federal health officials this spring to recommend a pause in the use of Johnson & Johnson’s vaccine. “I’ve been waiting for this moment for a long time,” said Heather Schmidt, of Ventura County, who is severely allergic to an ingredient in the available vaccines, so is unprotected. “This has been an incredibly stressful couple of years, and I really felt abandoned. I do not understand why every other country has more options than Americans.”
Australia Latest News, Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novavax hoping its COVID-19 vaccine using traditional technology wins over vaccine skepticsThe Novavax COVID-19 vaccine is made with an old school technology, but will it be enough to win over vaccine skeptics?
Read more »
FDA advisers meeting on Novavax, a latecomer in COVID-19 vaccine raceA federal advisory committee will vote on whether regulators should authorize a COVID-19 vaccine made by Novavax. From The New York Times.
Read more »
Novavax Covid-19 Vaccine Faces FDA Advisers’ ScrutinyThe outside panel of experts will vote on whether the shot should be authorized, after the agency found it effective but flagged a safety concern.
Read more »
Novavax Faces High Stakes FDA Review This Week That Will Decide the Fate of Its Covid Vaccine in the U.S.The Food and Drug Administration’s independent experts will review the safety and effectiveness of Novavax’s Covid vaccine Tuesday. If they endorse the vaccine, the FDA will almost certainly authorize the shot for adults in the U.S. Novavax’s vaccine uses protein technology that is different Pfizer and Moderna’s messenger RNA shots. Novavax was part of the U.S. race to develop a…
Read more »
FDA panel to review Novavax candidate as potential fourth vaccine for adult Americans, and Pete Buttigieg tests positive for COVIDAn advisory panel to the U.S. Food and Drug Administration is due to meet later Tuesday to review the vaccine developed by Novavax Inc. as a potential fourth...
Read more »
We Can't Keep Getting The Same Formula in COVID-19 Booster Shots, Says ImmunologistBeing up to date on COVID-19 vaccines means having had three or four doses of the same shot at this point. Current boosters are the same formulations as the first authorized shots, based on the original strain of the coronavirus that emerged in late
Read more »